{"entity":{"id":"nct07586943","kind":"trial","name":"SKB118 Injection in Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of SKB118 Injection in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","summary":"SKB118 Injection in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07586943 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 530 participants planned, started 2026-06-01 and due to reach its primary completion in 2029-12. Interventions recorded: SKB118 Injection and SKB118+SKB264.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07586943","url":"https://clinicaltrials.gov/study/NCT07586943"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["kelun-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07586943","phase":"1/2","setting":"A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SKB118 Injection in Participants With Advanced Solid Tumors","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","enrolled":530,"outcomes":[]},"route":"/trials/nct07586943/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/"}]}}